Literature DB >> 12487811

Characterizing immune reconstitution after long-term highly active antiretroviral therapy in pediatric AIDS.

Salvador Resino1, Rafael Correa, José M Bellón, Silvia Sánchez-Ramón, M Angeles Muñoz-Fernández.   

Abstract

In this study, we sought to characterize the T lymphocyte recovery in vertically HIV-1-infected children who respond to long-term highly active antiretroviral therapy (HAART). A 3-year longitudinal retrospective study was used to perform a cross-sectional study of 32 children rated according to the time course of CD4(+) T cell percentages in response to antiretroviral therapy and CDC clinical classification: (1) long-term asymptomatic (LTA group): 8 children in A1 during the whole follow-up period; (2) responsive to HAART (Rec group): 13 children in C3 before HAART who achieved CD4(+) T cell counts of > 500 cells/mm(3) after 3 years of HAART; and (3) nonresponsive to HAART (Non-Rec group): 11 children in C3 during the whole follow-up period despite 3 years of HAART. We also studied 17 healthy age-matched uninfected children as controls. Lymphoproliferative responses (LPRs) were evaluated by incorporation of [(3)H]thymidine, identification of T cell subsets by three-color flow cytometry, and determination of thymic production of T cells by quantification of T cell receptor rearrangement excision circles (TRECs). Interestingly, the Rec group showed an increase in percentage of CD4(+) T cells and a decrease in viral load, and recovered LPRs to mitogens and recall antigens, with values similar to those of the LTA group. Moreover, the Rec group produced similar percentages and absolute counts of naive (CD45RA(+)CD62L(+)) CD4(+) and CD8(+) T cells, and TRECs similar to those of the LTA group. In particular, the Rec group produced similar percentages of CD8(+)CD28(-)CD57(+) and CD8(+)CD28(-)CD57(-) T cell subsets compared with controls. Our data indicate that among children who have already progressed to AIDS and severe immunodeficiency but who respond to HAART, the immune system can recover and resemble those of nonprogressors or even uninfected children, in quantitative as well as in functional terms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12487811     DOI: 10.1089/088922202320935474

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  Cellular immune responses in human immunodeficiency virus (HIV)-1-infected children: is immune restoration by highly active anti-retroviral therapy comparable to non-progression?

Authors:  M Hainaut; V Verscheure; M Ducarme; L Schandené; J Levy; F Mascart
Journal:  Clin Exp Immunol       Date:  2011-04-19       Impact factor: 4.330

2.  Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART).

Authors:  Natascha Ching; Jaime G Deville; Karin A Nielsen; Bonnie Ank; Lian S Wei; Myung Shin Sim; Steven M Wolinsky; Yvonne J Bryson
Journal:  Eur J Pediatr       Date:  2006-07-26       Impact factor: 3.183

3.  Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children.

Authors:  Salvador Resino; Isabel Galán; José M Bellón; M Luisa Navarro; Juan Antonio León; M Angeles Muñoz-Fernandez
Journal:  J Clin Immunol       Date:  2003-07       Impact factor: 8.317

4.  Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy.

Authors:  Salvador Resino; Elena Seoane; Alicia Pérez; Ezequiel Ruiz-Mateos; Manuel Leal; Maria A Muñoz-Fernández
Journal:  BMC Infect Dis       Date:  2006-07-13       Impact factor: 3.090

5.  Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.

Authors:  Marie-Quitterie Picat; Joanna Lewis; Victor Musiime; Andrew Prendergast; Kusum Nathoo; Addy Kekitiinwa; Patricia Nahirya Ntege; Diana M Gibb; Rodolphe Thiebaut; A Sarah Walker; Nigel Klein; Robin Callard
Journal:  PLoS Med       Date:  2013-10-29       Impact factor: 11.069

6.  Computed CD4 percentage as a low-cost method for determining pediatric antiretroviral treatment eligibility.

Authors:  Steven F J Callens; Faustin Kitetele; Jean Lusiama; Nicole Shabani; Samuel Edidi; Robert Colebunders; Frieda Behets; Annelies Van Rie
Journal:  BMC Infect Dis       Date:  2008-03-06       Impact factor: 3.090

7.  Use of tuberculin skin test for assessment of immune recovery among previously malnourished children in Ethiopia.

Authors:  Paluku Bahwere; Philip James; Alemseged Abdissa; Yesufe Getu; Yilak Getnet; Kate Sadler; Tsinuel Girma
Journal:  BMC Res Notes       Date:  2017-11-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.